Results 51 to 60 of about 12,730 (256)

Reasons for patient reluctance to take preventive medications for migraine: Results of the OVERCOME (US) study

open access: yesHeadache: The Journal of Head and Face Pain, Volume 66, Issue 4, Page 846-858, April 2026.
Abstract Objectives/Background This study was undertaken to evaluate patient reasons for nonadoption of migraine‐preventive medications. Despite clear recommendations and eligibility criteria for migraine‐preventive treatment by the American Headache Society and the availability of these treatments, many people with migraine are not taking appropriate ...
Jessica Ailani   +9 more
wiley   +1 more source

From Līlā to Nitya and Back: Śrī Rāmakṛṣṇa and Vedānta

open access: yesReligions, 2020
There has been a long-standing academic debate on the religious orientation of Śrī Rāmakṛṣṇa Paramahaṁsa (1836–1886), one of the leading religious figures of modern India.
Arpita Mitra
doaj   +1 more source

Assessment of the occupational stress among nuclear medicine technical professionals in India

open access: yesClinical Epidemiology and Global Health, 2021
Background: Occupational stress has become subject of focus for studies involving healthcare professionals and it is a serious health issue. Occupational stress can lead to several negative consequences not only to the professionals but also for those ...
Sanny Bhushan Kumar   +3 more
doaj   +1 more source

Book Review: \u3cem\u3eHindu Christian Faqir: Modern Monks, Global Christianity, and Indian Sainthood\u3c/em\u3e [PDF]

open access: yes, 2016
Book Review of Hindu Christian Faqir: Modern Monks, Global Christianity, and Indian Sainthood. Timothy S. Dobe.
Corigliano, Stephanie
core   +2 more sources

Integrating gepants into clinical practice for the acute treatment of migraine

open access: yesHeadache: The Journal of Head and Face Pain, Volume 66, Issue 4, Page 976-989, April 2026.
Abstract Objective To assess the role of small‐molecule calcitonin gene–related peptide receptor antagonists (gepants) in the acute treatment of migraine, particularly in relation to triptan treatments. Background Triptans have established efficacy and are widely prescribed for the acute treatment of migraine.
Richard B. Lipton   +4 more
wiley   +1 more source

Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study

open access: yesThe Journal of Headache and Pain, 2018
Background The MAST Study is a longitudinal, cross-sectional survey study of US adults with migraine. These analyses were conducted to estimate rates of acute medication overuse (AMO) and determine associations of AMO with individual and headache ...
Todd J. Schwedt   +7 more
doaj   +1 more source

Introductory Information and Editor\u27s Preface [PDF]

open access: yes, 1997
Information about the publication, such as the Editorial Advisory Board and the Editorial Policy, and the Editor\u27s Preface for the ...
Coward, Harold
core   +2 more sources

Healthcare Resource Utilization and Cost After Temperature‐Controlled Radiofrequency Treatment of Nasal Airway Obstruction: A Real‐World Longitudinal Claims Analysis

open access: yesInternational Forum of Allergy &Rhinology, Volume 16, Issue 3, Page 261-271, March 2026.
ABSTRACT Background Nasal airway obstruction (NAO) is prevalent with substantial health and quality of life burdens. Nasal valve collapse (NVC) is one structural cause of NAO. Temperature‐controlled radiofrequency (TCRF) nasal valve remodeling offers an alternative to invasive surgery.
David W. Kennedy   +7 more
wiley   +1 more source

Book Review: Hindu Wisdom for all God\u27s Children [PDF]

open access: yes, 1999
A review of Hindu Wisdom for all God\u27s Children by Francis X ...
Sarma, Deepak
core   +2 more sources

Long‐Term Improvements Following Initial Migraine Response in Eptinezumab‐Treated Participants With Migraine for Whom 2–4 Prior Preventive Treatments Have Failed

open access: yesEuropean Journal of Neurology, Volume 33, Issue 3, March 2026.
This post hoc analysis of data from the DELIVER trial evaluated long‐term maintenance of early ≥ 50% and ≥ 75% migraine response. For both eptinezumab doses (100 or 300 mg), ≥ 50% or ≥ 75% migraine response over Weeks 1–12 or 1–24 was maintained for the entire 72‐week treatment period for many participants.
Jessica Ailani   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy